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The aim of this study is to investigate in vivo and ex vivo ocular surface alterations induced by dry eye disease and modification
after osmoprotective therapy. Forty-eight eyes of 24 patients suffering from dry eye have been recruited. All patients received
Optive (compatible solutes) eye drops in one randomly selected eye and Hylogel (sodium hyaluronate 0,2%) in the other. Follow-
up included a baseline visit and further examination 30-, 60-, and 90-day intervals (which comprises clinical evaluation, in vivo
confocal microscopy—IVCM—of the ocular surface, and conjunctival impression cytology). No significant difference in Schirmer
I Test, TBUT, and vital staining results was observed during the follow-up period in both groups. IVCM showed in all patients an
improvement of ocular surface epithelial morphology and signs of inflammation (oedema and keratocyte activation). However,
these modifications were more evident in patients treated with Optive therapy. A significant reduction of the expression of MMP9
and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment. Our results show that in
dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface,
with consequent improvement of the quality of corneal and conjunctival epithelium.
1. Introduction
Dry eye syndrome (DES) is a multifactorial disease of the
functional lacrimal unit, formed by lacrimal gland, adnexae,
tear film, and ocular surface. Dry eye alters and dam-
ages corneal and conjunctival epithelium, producing specific
symptoms and visual disturbances [1].
In dry eye patients, the ocular surface becomes dif-
fusely irregular with consequent differentiation of the epithe-
lial cells. DES can produce an irregularity of corneal
epithelial continuity with punctate or widespread defects. In
conjunctiva there is also a reduction of goblet cell density [2].
The exact mechanism by which these changes occur has
not been clarified, but it may be linked to hyperosmolar
tear film stress. The osmotic stress causes a modification
of corneal epithelium which determines an increase of the
stratum corneum, precursors of cellular coating [2].
Chronic inflammation and hyperosmolarity play an
important role in the genesis and maintenance of dry eye,
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since they are both the cause and the consequence in a
pathological self-renewing cycle [1].
The osmolarity of the tear film is determined by the pres-
ence of cations (sodium, potassium, calcium, magnesium,
and iron) and anions (chloride, bicarbonate, and phosphate)
[3].
It has been shown that the cellular hypertonicity of
different organisms could be compensated by compatible
solutes, which balance the osmotic pressure and do not
interfere with cellular metabolism [4]. These solutes include
amino acids, carbohydrates, methylamine, and urea [4, 5].
They are also considered osmoprotective substances which
can improve cellular survival under hypertonicity conditions.
These molecules are used by cells to introduce liquids in the
intracellular area and maintain cellular volume [5].
Experimental data, obtained on cultured corneal epithe-
lial cells, show that compatible solutes, as L-carnitine, ery-
thritol, and betaine, can suppress matrix metalloproteinase
(MMP) production and activation [6] and expression of
proinflammatory cytokines (TNF-𝛼, IL-1𝛽, and IL-6) and
chemokines (IL-8, CCL2, and CCL20) [7] without any
modifications of cellular metabolism. In fact, they are able
to hydrate and induce an osmoprotective effect on the
ocular surface. These macromolecules introduce liquids in
the intracellular area producing a direct hydration and a
natural osmoprotection [6, 8].
The aim of this study is to investigate, in vivo and ex
vivo, ocular surface alterations and inflammation in DES and
modifications related to the use of compatible solutes eye
drops.
2. Material and Methods
2.1. Patient’s Enrolment and Study Design. This study was
conducted at the Department of Medicine and Ageing
Science of the G. d’Annunzio University of Chieti-Pescara,
Italy. The protocol used was approved by the institutional
review and the study was conducted in concordance with the
tenets of the Declaration of Helsinki. Informed consent was
obtained from all the participants after explanation of the
nature and the possible consequences of the study.
48 eyes of 24 patients, 15 women and 9 men, age range
19–64 years, affected by DES have been recruited.
Inclusion criteria were as follows: current use of artificial
tears, Schirmer I Test< 8mm, and tear break-up time (TBUT)
< 8 seconds. Exclusion criteria were as follows: age <18
years, pregnant or lactating women, ocular surgery within
the last three months, presence of eye infection, presence of
glaucoma, and inadequate lid closure.
Recruited patients were treated by using a combination
of sodiumcarboxymethylcellulose (0.5%) and glycerol (0.9%)
eye drops (Optive, Allergan Inc.) 4 times daily for 90 days in
one randomly selected eye, and the comparator eye (control
eye) underwent therapy with sodium hyaluronate 0,2% eye
drops (Hylogel, Visufarma spa) 4 times daily for 90 days.
Patients were followed up at 30, 60, and 90 days.
At the baseline and follow-up visits, the following param-
eters have been assessed: Schirmer I Test, TBUT, lissamine
green staining of the ocular surface graded by the Lemp
classification [9], in vivo confocal microscopy (IVCM), and
impression cytology of bulbar conjunctiva.
2.2. In Vivo Confocal Microscopy. At each follow-up visit,
microscopic assessment of the ocular surface epithelial health
was performed by using IVCM(RostokCorneaModule-HRT
2, Heidelberg).
In each eye examined, at least 100 images of corneal
epithelium and 100 images of conjunctival bulbar epithelium
in nasal and temporal sector were acquired.
The analysed parameters were regularity of the corneal
and conjunctival epithelium and evaluation of inflammation
within the ocular surface.The presence of inflammatory cells
in subepithelial layer and anterior stroma was considered as
a marker of inflammatory activation. Adobe Photoshop pro-
gram (Adobe Systems Inc., Jose, CA) was used to define picks
of reflectivity from confocal microscopy images. Stromal
reflectivity was considered an indirect sign of the presence of
oedema and keratocyte activation.
2.3. Impression Cytology. Conjunctival impression cytology
samples were collected at each follow-up visit usingMillicell-
CM 0.4 𝜇m (Millipore, Bedford, MA) and the cells were fixed
with cytology fixative (Biofix, Bio Optica, Milano, Italy).
The Millicell membranes were hydrated with distilled
water; 80% alcohol was added for 2min. The membranes
were washed in distilled water and Phosphate Buffered Saline
(PBS) was added for 2min, followed by 2 washes with Wash
Buffer (Dako, Glostrup, Denmark) of 2min each. Then,
RibonucleaseA (Sigma-Aldrich, St. Louis,MO) diluted 1 : 290
in PBS was incubated for 20min at room temperature. The
specimens were washed and PBS-BSA 1% was added for 1
hour at room temperature. Finally, MMP9 antibody (Dako)
diluted 1 : 50 and IL6 antibody (Abcam, Cambridge, UK)
at 1 : 200 both in antibody diluent (Dako) were incubated
overnight at 4∘C. Samples were washed and anti-rabbit
Alexa fluor 488 (Invitrogen, San Giuliano Milanese, Italy)
diluted 1 : 200 and propidium iodide at 1 : 150 were added
and incubated for 1 hour at room temperature. Membranes
were mounted with a drop of Fluorescent MountingMedium
(Dako) and Zeiss Confocal LSM 510 (Carl Zeiss MicroImag-
ing GmbH, Vertrieb, Germany) was used to visualize the
cells.
Five different fields for each impression cytology sam-
ple were evaluated. Positive (red nucleus and green cyto-
plasm) and negative (red nucleus) cells were counted and
the positivity percentage was calculated. All evaluations
of impression cytology specimens were performed by two
independent observers masked to the details of the staining
technique used. Digital images of representative areas were
taken.
2.4. Statistical Analysis. Differences in markers expression
for selected antigens were assessed using the Student
unpaired 𝑡-test (GraphPad Prism 5, GraphPad Software, San
Diego, CA).
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Figure 1: IVCM images of ocular surface in dry eye. (a) Squamous metaplasia of conjunctival epithelium. (b) Irregularity and desquamation
of conjunctival epithelium. (c–f) Improving of quality and regularity of conjunctival epithelial cells more evident after 90 days of Optive
treatment (c-d) with respect to Hylogel group (e-f).
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Figure 2: IVCM images of ocular surface inflammation in dry eye. (a) Numerous activated keratocytes in corneal anterior stroma. (b) High
number of dendritic cells in corneal subepithelium. (c–f) Reduction of inflammation signs in corneal stroma and subepithelial layer, more
evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
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Figure 3: Immunofluorescence staining of impression cytology. (a–c) Cytoplasmic MMP9 staining in conjunctival cells at baseline (a) and
its significant reduction observed after 90 days of Optive (b) and Hylogel (c) therapy. (d–f) Expression of IL6 in conjunctival cells at day 0
(d) and its downmodulation at the end of the treatment in Optive (e) and Hylogel (f) groups. Original magnification ×630.
3. Results
3.1. Clinical Outcomes. Schirmer I Test and TBUT did not
show a significant modification during the follow-up period,
either in Optive or in Hylogel treated eyes; moreover, no
significant differences were revealed between the two groups.
Lissamine green staining of the ocular surface evalu-
ated by means of Lemp classification showed a significant
improvement of ocular surface epithelial regularity in both
groups at the end of follow-up period. No significant differ-
ences were observed between the two groups.
3.2. IVCM. In both groups, the morphology of corneal and
conjunctival epithelia showed an improvement during the
follow-up period. Comparing baseline images with findings
at 30, 60, and 90 days after treatment, a decrease in reflectivity
of superficial cells was observed together with an increase
of regularity of cell shape and size. No morphological differ-
ences were revealed between the two groups (Figure 1).
Stromal reflectivity showed a significant decrease both
in Optive group (𝑝 = 0,0009) and in Hylogel group
(𝑝 = 0,0400) at the end of follow-up period. Moreover,
a significant difference was observed at 90 days comparing
the two treatment groups (𝑝 = 0,0009) (Figure 2).
3.3. ImpressionCytology: Evaluation ofMMP9 and IL6 Expres-
sion. The immunofluorescence staining of the conjunctival
samples is shown in Figure 3.
MMP9 expression was significantly downmodulated in
Optive treated eyes at 30 (𝑝 = 0,0018) and 60 and 90 (𝑝 <
0,0001) days of therapy when comparing the two treatment
groups (Figure 4(a)).
Comparing the variations of the expression of MMP9
from day 0 to day 90, a gradual but strong reduction was
achieved in Optive group (𝑝 < 0,0001), while no significance
was observed in Hylogel treated eyes (Figure 4(a)).
IL6 positivity in conjunctival samples revealed signifi-
cant differences between Optive and Hylogel group when
observed 30 (𝑝 < 0,0001), 60 (𝑝 < 0,0001), and 90 days (𝑝 <
0,0001) after treatment (Figure 4(b)). Moreover, a significant
reduction was achieved among Optive treated eyes during all
of the follow-up period (day 0 versus 90𝑝 < 0,0001), while no
modifications were observed in Hylogel group (Figure 4(b)).
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Figure 4: Statistical analysis of MMP9 (a) and IL6 (b) expression in Hylogel (black bars) and Optive (white bars) groups at baseline (day 0)
and its variations during follow-up period (30, 60, and 90 days). Data are expressed as mean ± SEM. The unpaired Student’s 𝑡-test was used
to evaluate differences in markers expression. Significant 𝑝 values are reported.
4. Discussion
Hyperosmolarity represents an inflammatory stress to the
limbal and corneal epithelium, inducing the expression
of proinflammatory cytokines and metalloproteinase which
produce an increase of desquamating cellular processes and
nucleus/cytoplasm ratio and a reduction of cellular intercon-
nections [10]. Tear film osmolarity depends on the dynamic
modification of the tear film balance resulting from the
production, retention, and elimination of tears. It was also
related to the lacrimal flow and evaporation [2].
The increase of tear film osmolarity determines a reduc-
tion of conjunctival goblet cells, responsible for mucin pro-
duction with consequent epithelial damage [11].
An in vivo study on mice, testing the effect of topical
application of betaine, L-carnitine, and erythritol, showed a
significant reduction in number of TUNEL-positive cells and
expression of inflammatory mediators [12].
As already observed by Wei and colleagues, the inflam-
matory mediators associated with DES pathogenesis can be
divided as follows: (i) ubiquitous inflammatory cytokines,
(ii) Th1- and (iii) Th17-related cytokines, (iv) chemokines
and their receptors, (v) metalloproteinase, and (vi) secretory
phospholipases [13].
MMPs play a crucial role in initiating and maintaining
ocular surface damage [14].
MMP9 is the most important gelatinase present on the
ocular surface, and its levels seem to be higher in tears of
patients with dry eye [15]. Desiccating stress was found to
increase MMP9 in a murine model [16].
The conjunctival expression of MMP9 in DES patients
is already assessed [17]. Moreover, MMPs are responsible
for the extracellular matrix destruction observed in various
diseases as arthritis, cancer, and autoimmune disorders
[18, 19]. Under stress conditions, such as hyperosmolarity
[11, 20], MMP9 is released by the ocular surface cells [21].
Furthermore, MMP9 has been demonstrated to accelerate
corneal epithelial regeneration in the healing process by
modulating the inflammatory response. Therefore, the
increase of MMP9 activity on the ocular surface can amplify
the chronic immune-based inflammation of dry eye [21].
In our study, the downmodulation of MMP9 expression
in compatible solutes treated eye is linked to a clinical
improvement of the ocular surface epithelia, suggesting
a key role of MMP9 in the physiopathology of the dis-
ease.
The expression of IL6 was assessed as marker of con-
junctival inflammation status. The increased IL6 levels in
the ocular epithelium indicate an active immune state of the
microenvironment [22].
In Sjo¨gren syndrome, the ocular surface epithelium is a
target of the autoimmune process [23], and increased levels
of IL6 could be referred to as the direct involvement of the
conjunctiva in the pathogenic mechanism of the disease,
indicating a relevant role in ocular surface inflammatory
damage [17].
Our data showed a decreased positivity for IL6 induced by
osmoprotective treatment, suggesting an active downmodu-
lation of inflammatory response.
Mediators of Inflammation 7
The expression of MMP9 and IL6 in dry eye patients may
indicate that inflammatory mechanisms play a synergistic
role in the development of the disease.
The osmoprotectants compatible solutes, alone or in
combination, were found to protect against stress activation
of corneal epithelial cells cultured in hyperosmolarmedia [6–
8].
Clinical studies on human subjects suffering from DES
evidenced a noninferior efficacy and safety of the osmopro-
tective compatible solutes therapy with respect to standard
sodium hyaluronate treatment [24].
In vivo confocal microscopy and immunofluorescence
staining of impression cytology specimens were previously
used in combination to assess modifications of conjunctival
and corneal epithelia due to aging or limbal pathologies
[25, 26].
Several discordant results are reported in literature about
the real effect of hyaluronic acid compounds and Optive
on BUT and Schirmer test values [24, 27–32]; however,
difference in inclusion criteria, molecules concentration, and
daily dosage may explain the variability of the outcome.
In our results, no changes were observed in BUT and
Schirmer test values in both treatment groups, suggesting
that both therapies are not able to increase the quantitative
production of tears or to improve the lipidic component of the
tear film.This finding may be related to our inclusion criteria
of enrolled patients suffering from severe form of DES.
The real clinical effect of osmoprotection on ocular sur-
face is therefore represented by an improvement of epithelia
regularity as a consequence of better and specific inflamma-
tion control.
5. Conclusions
In conclusion, the ex vivo results of this study indicate that
treatment based on compatible solutes eye drops in DES
determines better control of ocular surface inflammatory
activation, with respect to hyaluronic acid therapy. The
effect of the decrease of inflammation is revealed in vivo
by an improvement of corneal and conjunctival epithelium
morphology together with a reduction of corneal stromal
reflectivity. In view of this data, osmoprotective approach can
represent, alone or in combination, a valid strategy in DES
management.
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